Sigthorsson Gudmundur, Simpson Robert J, Walley Matthew, Anthony Andrew, Foster Russell, Hotz-Behoftsitz Christoph, Palizban Abbas, Pombo Joaquim, Watts Jo, Morham Scott G, Bjarnason Ingvar
Department of Medicine, Guy's, King's, St. Thomas' Medical School, London, England.
Gastroenterology. 2002 Jun;122(7):1913-23. doi: 10.1053/gast.2002.33647.
BACKGROUND & AIMS: The pathogenesis of nonsteroidal anti-inflammatory drug-induced enteropathy is controversial, but it is thought that cyclooxygenase-1 (COX-1) inhibition is of pivotal importance. We compared small intestinal function and morphology in untreated wild-type, COX-1- and COX-2-deficient mice and the effect of indomethacin, selective COX-1 (SC-560), and COX-2 (celecoxib) inhibition.
Intestinal permeability ((51)CrEDTA), inflammation (fecal granulocyte marker protein), prostaglandin E(2) (PGE(2)) levels, and macroscopic and microscopic appearances were assessed at baseline and after the drugs.
COX-1(-/-) animals were normal except for a 97% decrease in intestinal PGE(2) levels. COX-1(+/+) and COX-1(-/-) animals reacted in a similar way to indomethacin. However, celecoxib, having caused no damage in COX-1(+/+) animals, caused small bowel ulcers in COX-1(-/-) animals. Selective inhibition of COX-1 decreased intestinal PGE(2) levels in COX-2(+/+) and COX-2(-/-) animals by 95%-97%, but caused only small bowel ulcers in the latter group. Dual inhibition of COX-1 and COX-2 in wild-type animals resulted in similar small bowel damage. Between 40% and 50% of untreated COX-2(-/-) animals had increased intestinal permeability and inflammation. Some had ileal ulcers that were distinctively different from indomethacin-induced ulcers. Furthermore, long-term celecoxib administration in wild-type animals was associated with similar damage as in the COX-2(-/-) mice.
COX-1 deficiency or inhibition and short-term COX-2 inhibition are compatible with normal small intestinal integrity. Dual inhibition of the COX enzymes leads to damage similar to that seen with indomethacin. Long-term COX-2 deficiency or inhibition is associated with significant intestinal pathology despite normal intestinal PGE(2) levels, suggesting a role for COX-2 in the maintenance of small intestinal integrity in the mouse.
非甾体抗炎药所致小肠病的发病机制存在争议,但普遍认为环氧合酶-1(COX-1)抑制起关键作用。我们比较了未经处理的野生型、COX-1和COX-2基因敲除小鼠的小肠功能和形态,以及吲哚美辛、选择性COX-1抑制剂(SC-560)和COX-2抑制剂(塞来昔布)的作用。
在基线及用药后评估肠道通透性((51)CrEDTA)、炎症(粪便粒细胞标记蛋白)、前列腺素E2(PGE2)水平以及大体和显微镜下表现。
COX-1基因敲除(-/-)动物除肠道PGE2水平降低97%外,其余均正常。COX-1基因野生型(+/+)和COX-1基因敲除(-/-)动物对吲哚美辛的反应相似。然而,塞来昔布在COX-1基因野生型(+/+)动物中未造成损伤,但在COX-1基因敲除(-/-)动物中导致小肠溃疡。选择性抑制COX-1可使COX-2基因野生型(+/+)和COX-2基因敲除(-/-)动物的肠道PGE2水平降低95%-97%,但仅在后一组动物中导致小肠溃疡。野生型动物中COX-1和COX-2的双重抑制导致类似的小肠损伤。40%-50%未经处理的COX-2基因敲除(-/-)动物肠道通透性增加且有炎症。部分动物有回肠溃疡,与吲哚美辛所致溃疡明显不同。此外,野生型动物长期给予塞来昔布与COX-2基因敲除(-/-)小鼠出现类似损伤。
COX-1缺乏或抑制以及短期COX-2抑制与小肠完整性正常相符。COX酶的双重抑制导致与吲哚美辛相似的损伤。尽管肠道PGE2水平正常,但长期COX-2缺乏或抑制与显著的肠道病变相关,提示COX-2在维持小鼠小肠完整性中起作用。